Biotechnology powerhouse Novozymes has repeatedly turned to David Tellekson for his expertise in enforcing patent rights. Novozymes celebrated its first trial win with Mr. Tellekson in 2006 in the District of Delaware, obtaining a judgment of willful infringement, followed by an award of double damages and attorneys’ fees, against Genencor. It was therefore not surprising that Novozymes again hired Mr. Tellekson and his Fenwick team to pursue Danisco, a subsidiary of DuPont, in a patent case involving genetically modified proteins. The Fenwick team filed suit against Danisco in the rocket docket of the Western District of Wisconsin in May 2010 and tried the case to a jury in October 2011. After returning a unanimous verdict of willful infringement and validity, the jury awarded Novozymes $18.2 million in damages
The Fenwick & West team was led by David Tellekson and Virginia DeMarchi, together with partner Brian Buckley and associates Melanie Mayer, Jeffrey Lasker, Ewa Davison, Michael Saunders, Jeffrey Ware and David Austin.
Fenwick's Life Sciences Patent Litigation Group has a track record of success in federal jurisdictions throughout the United States. The group is backed by unique science and technology credentials with in-house expertise and enhanced synergy from Fenwick's 45+ patent prosecution professionals, many with Ph.D. and other advanced technical degrees in disciplines such as molecular biology, organic chemistry, electrical engineering and immunology. The firm was recently ranked by Corporate Counsel as one of the 2011 Top 10 "Go-To" IP litigation firms in the U.S. for Fortune 100 companies and by IP Worldwide as one of the top dozen firms that Fortune 500 companies relied on for IP litigation.